Skip to main content
Adriene Marques)

Our Company

Driven by Our Promise

It began with a promise. CSL, was formed more than 100 years ago to save lives using the latest technologies. In the century since, CSL has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in our industry. Our ability to innovate and deliver life-saving medicines for patients with rare disease and other unmet medical needs around the world has earned us a reputation for always putting patients first. We are CSL and we are driven by our promise.

Two scientists in a lab

Focus on Rare & Serious Diseases

Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 Antitrypsin Deficiency.

Learn More

CSL Behring's Australian manufacturing site in Broadmeadows, Victoria

Broadmeadows Manufacturing Facility

Australia has a longstanding commitment to a policy of self-sufficiency in the production and supply of blood and plasma products. Under Australia’s National Blood Agreement, security of supply for a comprehensive range of important plasma products is underpinned by their on-shore manufacture from Australia’s own plasma, which CSL Behring undertakes at our manufacturing facility in Broadmeadows Victoria.  CSL Behring manufactures a comprehensive portfolio of 15 plasma products for Australia from plasma collected by the Australian Red Cross Blood Service:

• Immunoglobulins to treat and prevent infections, and to treat autoimmune diseases and neurological conditions.
• Critical care products for use in blood loss, shock, to treat severe burns and to replace specific blood proteins.
• Coagulation factors to treat bleeding disorders such as haemophilia and von Willebrand disease, and to reverse the effects of warfarin.
• Hyperimmune immunoglobulins to help protect against infection by life-threatening bacteria or viruses, and to help prevent haemolytic disease of the newborn.

In addition to manufacturing plasma products from Australia’s plasma, CSL Behring’s facility in Broadmeadows Victoria also provides highly specialised contract plasma fractionation services to other countries in the region: New Zealand, Hong Kong, Malaysia, Singapore and Taiwan.

Since 2010 CSL Behring has invested in three substantial new manufacturing facilities at our Broadmeadows site.

Biotechnology Manufacturing Facility
• One of Australia’s largest and most advanced biotechnology facilities, for the manufacture of new recombinant protein therapies for use in late stage clinical development for a range of conditions.

Turner PRIVIGEN® Facility and AlbuRx® Facility
• PRIVIGEN (intravenous normal immunoglobulin, 10%) and AlbuRx (Human Albumin 5% & 25%) are global CSL Behring therapies manufactured from plasma collected by CSL Plasma in the US and Europe.
• Commissioning of these two facilities at Broadmeadows will substantially expand CSL Behring’s global production capacities and see product manufactured in Broadmeadows Victoria exported for supply to patients globally across the CSL Behring network, to meet growing global need for these important therapies.

In addition to contributing to Australia’s export economy, these three additional facilities at Broadmeadows will provide Australia with further high skills science and manufacturing employment opportunities, and strengthen capabilities to develop and commercialise future new medicines onshore in Australia.

Our Values

CSL’s strong commitment to living our Values has guided us for many decades. Our Values have been fundamental to our success -- helping us to save lives, protect the health of people, and earn our reputation as a trusted and reliable global leader. They’re at the core of how our employees interact with each other, make decisions and solve problems. They are:

Patient Grizalez

Patient Focus

We deliver on our promise to patients.

CSL Behring Bern employee Corinne Steiner holding a pipette

Innovation

We turn innovative thinking into solutions.

CSL Behring Employees

Integrity

We walk the talk.

Employees talking at a table

Collaboration

We are stronger together.

Superior Performance

We take pride in our results.

Paul Perreault

Global Leadership Group

The Global Leadership Group’s unwavering commitment to patients enables us to deliver on our obligations to all stakeholders.

Learn More